

Engagement Report for Clinical Commissioning Policies

Unique Reference Number	B13X04
Policy Title	Stereotactic radiosurgery/radiotherapy for ependymoma, haemangioblastoma, pilocytic astrocytoma and trigeminal schwannoma
Accountable Commissioner	Kim Fell
Clinical Reference Group	CNS Tumours
Which stakeholders were contacted to be involved in policy development?	All CRG members and registered stakeholders.
Identify the relevant Royal College or Professional Society to the policy and indicate how they have been involved	Representatives of relevant Royal College or Professional Societies were contacted for Stakeholder Testing as part of the CRG.
Which stakeholders have actually been involved?	All of the key stakeholders listed above were invited to comment.
Explain reason if there is any difference from previous question	Not applicable.

DRAFT FOR PUBLIC CONSULTATION ONLY

<p>Identify any particular stakeholder organisations that may be key to the policy development that you have approached that have yet to be engaged. Indicate why?</p>	<p>None</p>
<p>How have the stakeholders been involved? What engagement methods have been used?</p>	<p>The draft policy proposition and evidence review was circulated to the full membership of the CRG and registered stakeholders for their views, both to establish whether any amendments to the policy are required, and to understand from their perspective what the key questions to ask at consultation might be.</p> <p>Four responses were received – one from CRG members and three from stakeholders.</p> <p><u>The responses are summarised as follows:</u></p> <ol style="list-style-type: none"> 1. One stakeholder requested that the line of treatment for Trigeminal Schwannomas be clarified, noting the role of SRS/T as first-line treatment for this tumour type. 2. The stakeholder further noted that the patient pathway for paediatric and TYA patients be clarified. 3. Stakeholders requested further clarification on which Tier of service SRS/T is intended for. 4. One stakeholder requested a clarification of the MDT, suggesting an inclusion of a Clinical Oncologist.
<p>What has happened or changed as a result of their input?</p>	<p>The PWG have considered the responses and their views are summarised as follows:</p> <ul style="list-style-type: none"> - In response to (1) the PWG agreed and have updated the commissioning criteria in the policy proposition to reflect the place of SRS/T in the patient pathway for Trigeminal Schwannomas. - In response to (2) the PWG agreed and have updated the patient pathway clarifying the pathways for paediatric and TYA patients. - In response to (3) the PWG asked stakeholders to review the service specification, which details service Tiers. - In response to (4) the PWG asked stakeholders to review the service specification, which also details MDT requirements. <p>The following stakeholders will be contacted as part of public consultation: The National Centre for Stereotactic Radiosurgery and the Children's Cancer and Leukaemia Group.</p>
<p>How are stakeholders being kept informed of progress with policy development as a result of their input?</p>	<p>This engagement report, along with the updated policy proposition will be circulated as part of the public consultation. Stakeholders will be notified and invited to comment further.</p>

DRAFT FOR PUBLIC CONSULTATION ONLY

<p>What level of wider public consultation is recommended by the CRG for the NPOC Board to agree as a result of stakeholder involvement?</p>	<p>Public consultation for a period of 30 days as supported by stakeholders.</p>
--	--